TITLE

Other News To Note

PUB. DATE
April 2013
SOURCE
BioWorld International;4/3/2013, Vol. 18 Issue 14, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs on biotechnology companies. CureVac GmbH announced the start of Phase IIb trial for its RNActive cancer vaccine CV9104 in subjects with castration-resistant prostate cancer. Oncodesign SA and Sanofi SA reached a deal for a second joint venture on kinase. South Korea's SK Biopharmaceuticals forged a business deal with Chinese companies PKU International HealthCare Group and Shanghai Medicilon for the SKL-PSY molecule to treat depression and bipolar disorders.
ACCESSION #
86700950

 

Related Articles

  • Sipuleucel-T Suspension for Intravenous Infusion (Provenge). Elliott, William T.; Chan, James // Internal Medicine Alert;6/15/2010, Vol. 32 Issue 11, p85 

    The article provides information on Sipuleucel-T vaccine, a cellular immunotherapy suggested to treat prostate cancer.

  • First cancer vaccine approved for use in people.  // New Scientist;5/8/2010, Vol. 206 Issue 2759, p5 

    The article discusses a prostate cancer vaccine called Provenge that has been approved by the U.S. Food and Drug Administration (FDA) for use in humans.

  • Sanofi Collaborates with Oncodesign to Develop Inhibitors of Challenging Kinase Targets. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 9, p125 

    The article reports on the strategic research collaboration between Oncodesign SA and Sanofi SA. It states that the four-year collaboration, which is worth €130 million, involves the application of Oncodesign's medicinal chemistry technology and research platform called Nanocyclix® in...

  • Other News To Note.  // BioWorld Today;9/14/2012, Vol. 23 Issue 179, p2 

    This section offers news briefs on the pharmaceutical industry. Elusys Therapeutics Inc. has received additional funding from the U.S. government to support human safety studies of the investigational agent ETI-204. MonoSol Rx LLC is developing a migraine drug candidate which will utilize its...

  • Unique Treatment Raises Tricky Bioethical Issues. Yard, Delicia Honen // Renal & Urology News;Aug2010, Vol. 9 Issue 8, p28 

    The article discusses tricky bioethical issues related to the treatment of prostate cancer. It mentions that despite the benefits of vaccine for advanced castration-resistant prostate cancer, the treatment is an extremely high cost. It tackles the bioethical issue of the Provenge, a treatment...

  • Castrate-resistant prostate cancer. Black, Peter // Oncology Exchange;Aug2011, Vol. 10 Issue 3, p9 

    The article discusses the development of various treatments for castrate-resistant prostate cancer (CPRC). It reviews some of the treatments in treating patients with CPRC which include abiratorine, denosumab, and zoledronic acid. It highlights various breakthroughs in managing CPRC that...

  • Other News To Note.  // BioWorld Today;3/14/2013, Vol. 24 Issue 49, p2 

    The article offers news briefs on biotechnology companies as of March 14, 2013. The U.S. Food and Drug Administration has approved Lymphoseek injection, according to Navidea Biopharmaceuticals Inc. Oncodesign SA's Innovative MODels Initiative (IMODI) project will receive a 13.4 million-euro fund...

  • Sanofi Sponsors 2012 BIO Intl Convention, Jun 18 - 21 2012, in Boston MA, US.  // Biomedical Market Newsletter;6/18/2012, Vol. 21, p1 

    The article offers information on the Biotechnology Industry Organization (BIO) International Convention to be held at Boston, Massachusetts on June 18-21, 2012 which will be sponsored by Sanofi SA.

  • EDAP's Ablatherm granted temporary reimbursement.  // Medical Device Daily;2/4/2011, Vol. 15 Issue 24, p1 

    This article reports on a special temporary reimbursement for Ablatherm-HIFU for the treatment of localized prostate cancer received by EDAP TMS, a developer of therapeutic ultrasound products, from the French National Authority for Health (HAS). The grant follows a comprehensive review of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics